Description
Anti-IL-17α Antibody, Non-Fucosylated (BioBet-041ZP) is a human monoclonal IgG1 antibody against IL-17α. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Psoriasis
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL-17α antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Background
IL17A is a proinflammatory cytokine that is a member of the interleukin17 family. IL17A plays a central role in host defense against diverse pathogens. The active IL17A functions as either a homodimer with other interleukin17 family members and signals through the interleukin17 receptor to induce inflammatory cytokine production. IL17A is associated with autoinflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.
Alternative Names
Il17, Ctla8, IL-17, Ctla-8, IL-17A
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IL17A include Arthritis and Bronchiolitis Obliterans.
Related Pathways
Its related pathways are PEDF Induced Signaling and Immune response IL-23 signaling pathway.
Function
Ligand for IL17RA and IL17RC (PubMed:17911633). The heterodimer formed by IL17A and IL17F is a ligand for the heterodimeric complex formed by IL17RA and IL17RC (PubMed:18684971). Involved in inducing stromal cells to produce proinflammatory and hematopoietic cytokines (PubMed:8676080).
Field of research
Cancer antibody; Immune System antibody
Post-translational modifications
Found both in glycosylated and nonglycosylated forms.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-041ZP
Description
Secukinumab, sold under the trade name Cosentyx, is a human IgG1κ monoclonal antibody. Secukinumab inhibits interleukin 17A, a member of the cytokine family, for the treatment of psoriasis, ankylosing spondylitis and psoriatic arthritis
Antibody Indication
Ankylosing Spondylitis (AS)
Psoriatic Arthritis
Severe Plaque psoriasis
Moderate Plaque psoriasis
